An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson’s Disease and G2019S LRRK2 Cohorts

LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients

(2019) Farzaneh Atashrazm et al.   MOVEMENT DISORDERS

LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice

(2019) Michael X. Henderson et al.   Acta Neuropathologica Communications

Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development

(2019) Roy N. Alcalay et al.   MOVEMENT DISORDERS

LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies

(2016) Nicolas Dzamko et al.   MOVEMENT DISORDERS

Inhibitor treatment of peripheral mononuclear cells from Parkinson’s disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker

(2016) G. Perera et al.   Scientific Reports

Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases

(2016) Martin Steger et al.   eLife

Glucocerebrosidase activity in Parkinson’s disease with and withoutGBAmutations

(2015) Roy N. Alcalay et al.   BRAIN

Effect of selective LRRK2 kinase inhibition on nonhuman primate lung

(2015) Reina N. Fuji et al.   Science Translational Medicine

Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging

(2014) Francesco Longo et al.   NEUROBIOLOGY OF DISEASE

LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status

(2014) April Reynolds et al.   Frontiers in Molecular Neuroscience

Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology

(2012) Jing Zhao et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Ser1292 Autophosphorylation Is an Indicator of LRRK2 Kinase Activity and Contributes to the Cellular Effects of PD Mutations

(2012) Z. Sheng et al.   Science Translational Medicine

14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization

(2010) R. Jeremy Nichols et al.   BIOCHEMICAL JOURNAL